Replies to post #387 on MyMD Pharmaceuticals Inc (MYMD)

[leifsmith]

“Oravax is based on cutting edge technology from Oramed Pharmaceuticals & Premas Biotech.”

MyMD’s 10-Q for June 30, 2021: MyMD shows an investment in Oravax valued at $1,500,000.

Oravax uses Premas’ C-Crypt technology, and uses Oramed’s POD technology.

• https://ora-vax.com
• https://www.premasbiotech.com
• https://oramed.com

Thanks for tracking developments, knuts4oe